In vitro antifungal susceptibility methods and clinical implications of antifungal resistance

A. Espinel-Ingroff, D. W. Warnock, Jose Antonio Vazquez, B. A. Arthington-Skaggs

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

As new antifungal agents are introduced for the treatment of infections caused by yeasts and filamentous fungi (moulds), it is important that reliable methods are available for the in vitro testing of both new and established agents. The ultimate goal of in vitro testing is the prediction of the clinical outcome of therapy. The use of the M27-A procedures that were developed by the US National Committee for Clinical Laboratory Standards (NCCLS) has led to increased interlaboratory agreement of minimum inhibitory concentrations (MICs) for yeasts and has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole. The clinical relevance and limitations of these breakpoints are discussed elsewhere. The focus of this paper is to review the advantages and disadvantages of the available methods for antifungal susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal resistance.

Original languageEnglish (US)
Pages (from-to)293-304
Number of pages12
JournalMedical Mycology
Volume38
DOIs
StatePublished - Jan 1 2000

Fingerprint

Fungi
Yeasts
yeasts
molds (fungi)
fluconazole
Itraconazole
itraconazole
Fluconazole
Antifungal Agents
testing
Microbial Sensitivity Tests
minimum inhibitory concentration
committees
fungicides
methodology
therapeutics
fungi
prediction
Infection
infection

Keywords

  • Antifungal resistance
  • Moulds
  • Susceptibility testing
  • Yeasts

ASJC Scopus subject areas

  • Infectious Diseases

Cite this

In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. / Espinel-Ingroff, A.; Warnock, D. W.; Vazquez, Jose Antonio; Arthington-Skaggs, B. A.

In: Medical Mycology, Vol. 38, 01.01.2000, p. 293-304.

Research output: Contribution to journalArticle

Espinel-Ingroff, A. ; Warnock, D. W. ; Vazquez, Jose Antonio ; Arthington-Skaggs, B. A. / In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. In: Medical Mycology. 2000 ; Vol. 38. pp. 293-304.
@article{f95ce44127824c3a8562538a9ba87445,
title = "In vitro antifungal susceptibility methods and clinical implications of antifungal resistance",
abstract = "As new antifungal agents are introduced for the treatment of infections caused by yeasts and filamentous fungi (moulds), it is important that reliable methods are available for the in vitro testing of both new and established agents. The ultimate goal of in vitro testing is the prediction of the clinical outcome of therapy. The use of the M27-A procedures that were developed by the US National Committee for Clinical Laboratory Standards (NCCLS) has led to increased interlaboratory agreement of minimum inhibitory concentrations (MICs) for yeasts and has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole. The clinical relevance and limitations of these breakpoints are discussed elsewhere. The focus of this paper is to review the advantages and disadvantages of the available methods for antifungal susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal resistance.",
keywords = "Antifungal resistance, Moulds, Susceptibility testing, Yeasts",
author = "A. Espinel-Ingroff and Warnock, {D. W.} and Vazquez, {Jose Antonio} and Arthington-Skaggs, {B. A.}",
year = "2000",
month = "1",
day = "1",
doi = "10.1080/mmy.38.s1.293.304",
language = "English (US)",
volume = "38",
pages = "293--304",
journal = "Medical Mycology",
issn = "1369-3786",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - In vitro antifungal susceptibility methods and clinical implications of antifungal resistance

AU - Espinel-Ingroff, A.

AU - Warnock, D. W.

AU - Vazquez, Jose Antonio

AU - Arthington-Skaggs, B. A.

PY - 2000/1/1

Y1 - 2000/1/1

N2 - As new antifungal agents are introduced for the treatment of infections caused by yeasts and filamentous fungi (moulds), it is important that reliable methods are available for the in vitro testing of both new and established agents. The ultimate goal of in vitro testing is the prediction of the clinical outcome of therapy. The use of the M27-A procedures that were developed by the US National Committee for Clinical Laboratory Standards (NCCLS) has led to increased interlaboratory agreement of minimum inhibitory concentrations (MICs) for yeasts and has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole. The clinical relevance and limitations of these breakpoints are discussed elsewhere. The focus of this paper is to review the advantages and disadvantages of the available methods for antifungal susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal resistance.

AB - As new antifungal agents are introduced for the treatment of infections caused by yeasts and filamentous fungi (moulds), it is important that reliable methods are available for the in vitro testing of both new and established agents. The ultimate goal of in vitro testing is the prediction of the clinical outcome of therapy. The use of the M27-A procedures that were developed by the US National Committee for Clinical Laboratory Standards (NCCLS) has led to increased interlaboratory agreement of minimum inhibitory concentrations (MICs) for yeasts and has facilitated the establishment of interpretive breakpoints for fluconazole and itraconazole. The clinical relevance and limitations of these breakpoints are discussed elsewhere. The focus of this paper is to review the advantages and disadvantages of the available methods for antifungal susceptibility testing of yeasts and moulds as well as the clinical implications of in vitro antifungal resistance.

KW - Antifungal resistance

KW - Moulds

KW - Susceptibility testing

KW - Yeasts

UR - http://www.scopus.com/inward/record.url?scp=0034506745&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034506745&partnerID=8YFLogxK

U2 - 10.1080/mmy.38.s1.293.304

DO - 10.1080/mmy.38.s1.293.304

M3 - Article

VL - 38

SP - 293

EP - 304

JO - Medical Mycology

JF - Medical Mycology

SN - 1369-3786

ER -